Imviva Biotech Advances CTA313 CAR-T Program with FDA IND Approval
BOSTON, June 9, 2026 Imviva Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational...
Multiple Sclerosis
Advertisement
Roche Partners with Nurix to Advance BTK Degrader Bexobrutideg Across Cancer, Immunology and Neurology
BASEL, Switzerland, June 8, 2026 Roche announced a global licensing and collaboration agreement with Nurix Therapeutics to co-develop and...
Mabwell Receives NMPA Clearance for 9MW5211 in Inflammatory Bowel Disease
SHANGHAI, China, June 5, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug...
Halozyme and GSK Partner on Next-Gen ADC Cancer Therapies
SAN DIEGO, May 7, 2026 Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to...
Mabwell Wins FDA IND Clearance for 9MW5211 in IBD
SHANGHAI, China – May 8, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that...
Advertisements
Oculis Holding AG Secures FDA SPA for Privosegtor Optic Neuritis Phase 3 Trial
ZUG, Switzerland – May 7, 2026 Oculis Holding AG announced that the U.S. Food and Drug Administration (FDA) has...
Neuraly Inc Advances NLY01 Phase 2 MS Trial
GAITHERSBURG, Md., United States – May 2026 Neuraly Inc. has announced that the first patient has been dosed in...
SetPoint Medical Starts MS Study for Neuroimmune Therapy
VALENCIA, California, April 30, 2026 SetPoint Medical announced the first patients enrolled in a pilot clinical study evaluating its...
Sanofi Cenrifki Wins EU CHMP Boost for Progressive MS
PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...
Mapi Pharma GA Depot Shows Strong MS Progression Control
NESS ZIONA, Israel, April 16, 2026 Mapi Pharma Ltd. has announced new clinical findings demonstrating that its Glatiramer Acetate...
Advertisement
